-transparent.png){kind=logo}
Pergolide, a long-acting central dopamine agonist, was used as monotherapy in 16 parkinsonian patients. A mean daily dose of 6.3 mg resulted in 73% improvement of parkinsonian disability. Clinical improvement after acute administration of one dose of pergolide was similar to that observed after levodopa plus a peripheral decarboxylase inhibitor but at a dose 100 times lower (2.2 mg and 200 mg, respectively). The effect lasted twice as long (5 1/2 hours and 2 1/4 hours, respectively).
Related Publications
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
January 1984,
Advances in neurology,
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
March 1995,
Neurology,
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
April 1991,
The American journal of the medical sciences,
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
January 1995,
Journal of neural transmission. Supplementum,
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
December 1983,
Archives of neurology,
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
January 1991,
Archivos de neurobiologia,
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
January 1984,
Journal of neurology,
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
December 2003,
Current opinion in neurology,
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
October 1999,
Journal of neurology,
J Y Mear, and
G Barroche, and
Y de Smet, and
M Weber, and
F Lhermitte, and
Y Agid
January 1983,
Advances in neurology,
